- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00203203
Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
Randomized Controlled Single Blind Trial of Autologous Bone Marrow Mononuclear Cells Under Electromechanical Guidance for Therapeutic Angiogenesis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Heart Institute/Baylor St. Luke's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- LVEF less than 45%
- Functional class III or IV angina
- At least 7% reversibility by Single Photon Emission Computed Tomography (SPECT) nuclear study
- there are additional inc. criteria
Exclusion Criteria:
- AGe <18 or >70 years of age
- Constant atrial fibrillation
- Left ventricular (LV) thrombus
- History of malignancy in the last 5 years
- LV wall thickness of < 8 mm at the target site
- there are additional exclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Stem Cell Therapy
Subject is randomized to receive Stem Cell Therapy (intramyocardial injection of stem cells) via NOGA mapping.
|
Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
Other Names:
|
Other: Control, then Stem Cell Therapy
Subject is randomized to receive a NOGA mapping and no injections at time of active enrollment. At 6 months, subject is offered stem cell therapy. |
Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of Autologous-bone-marrow Injections
Time Frame: up to 2 weeks post-procedure, 3 months and 6 months
|
Safety of cell injections was assessed by reviewing adverse events at 3 time points: (1) up to 2 weeks post-procedure), (2) 3 months post-procedure, and (3) at 6 months post-procedure.
Major adverse events were adjudicated (hospitalization, arrhythmia, exacerbation of congestive HF [CHF], acute coronary syndrome, myocardial infarction, stroke, or death).
|
up to 2 weeks post-procedure, 3 months and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Canadian Cardiovascular (CCS) Angina Score
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Canadian Cardiovascular (CCS) Angina Score which indicates discomfort from angina (chest pain). Class I- Angina only during strenuous or prolonged activity Class II- Slight limitation, with angina only during vigorous physical activity Class III- Symptoms with everyday living activities (moderate limitation) Class IV- Inability to perform any activity without angina or angina at rest (severe limitation) |
baseline, 3 months and 6 months
|
New York Heart Association (NYHA)Classification
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using New York Heart Association (NYHA)Classification and indicates extent of heart failure based on limitations in physical activity. Class I- No symptoms/limitation in ordinary physical activity (shortness of breath when walking, etc) Class II-Mild symptoms/slight limitation during ordinary activity Class III- Marked limitation in activity due to symptoms, even during less-than-ordinary activity Class IV- Severe limitations in activity/experiences symptoms while at rest (bedbound) |
baseline, 3 months and 6 months
|
Myocardial Oxygen Consumption (MVO2)
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Myocardial Oxygen Consumption (MVO2)which is the amount of oxygen used by the heart muscle and is indicative of heart muscle function.
Normal value is 15.5 Volume %.
Measured as milliliters (ml) oxygen per kilogram (kg) body weight per minute.
|
baseline, 3 months and 6 months
|
Echocardiography (EF)Percent (%)
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography measures ejection fraction(EF)as a percentage(%) of blood leaving the heart with each beat or contraction.
It can provide information concerning structural characteristics and blood flow in the heart and blood vessels.
A normal heart pumps 50-75% of the blood with each contraction.
|
baseline, 3 months and 6 months
|
Minute Ventilation- Carbon Dioxide Production Relationship (VE/VCO2 Slope)
Time Frame: baseline and 3 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Minute Ventilation- Carbon Dioxide Production Relationship (VE/VCO2 slope)measure during a cardiopulmonary exercise test has a high prognostic value for survival in heart failure patients.
Normal VE (milliliters per minute)/VCO2 (milliliters per minute)equals 25.
|
baseline and 3 months
|
Echocardiography Wall Motion Score Index (WMSI)
Time Frame: baseline and 3 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Echocardiography Wall Motion Score Index (WMSI)which allows detection of abnormalities in the heart wall or blood flowing through the heart.
Normal contracting Left Ventricle has WMSI of 1. Larger WMSI indicates higher degree of abnormalities (2 for hypokinetic, 3 for akinetic, 4 for dyskinetic, and 5 for aneurysmal).
WMSI was calculated as the sum of scores divided by the total number of segments.
|
baseline and 3 months
|
Single-photon Emission Computed Tomography (SPECT) Imaging for Left Ventricular Ejection Fraction (LVEF) Percentage (%)
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Single-photon emission computed tomography (SPECT) imaging for Left Ventricular Ejection Fraction (LVEF) percentage (%)to determine how well the heart is pumping blood from the left ventricle.
Different method for evaluating how much (%) of blood is pumped through heart with each contraction.
|
baseline, 3 months and 6 months
|
Angiography Left Ventricular Ejection Fraction (LVEF) Percent (%)
Time Frame: baseline and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using angiography left ventricular ejection fraction (LVEF) percent (%) which is an invasive method used to estimate how well the heart is pumping blood through the ventricle and is considered the "gold" standard.
|
baseline and 6 months
|
Left Ventricular End-Diastolic Volume (LVEDV)
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Left Ventricular End-Diastolic Volume (LVEDV)which is the volume of blood inside the left ventricle when the heart has completed its filling cycle.
The volume of the left ventricle is measured during contraction and relaxation.
Normal heart volume inside the left ventricle is about 140 milliliters.
|
baseline, 3 months and 6 months
|
Left Ventricular End-Systolic Volume (LVESV) (ml)
Time Frame: baseline, 3 months and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Left Ventricular End-Systolic Volume (LVESV)when the blood moves from the ventricles to the atria during the contraction cycle.
Measured as volume in milliliters (ml).
Normal is approximately 60- 65 milliliters.
|
baseline, 3 months and 6 months
|
Endocardial Unipolar Voltages (UPV)
Time Frame: baseline and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Endocardial Unipolar Voltages (UPV)in millivolts(mV)which may be indicative of scar tissue.
Normal is <5.5 mV.
|
baseline and 6 months
|
Linear Local Shortening (LLS)
Time Frame: baseline and 6 months
|
Clinical and functional assessment in endstage ischemic cardiomyopathy patients using Linear Local Shortening (LLS)which is an indicator of mechanical properties of the heart and measured as a percentage (%)of local contraction.
|
baseline and 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Emerson Perin, MD,PhD., Texas Heart Institute/Baylor St Luke's Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSC-MS-04-141
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Cardiomyopathy
-
Cedars-Sinai Medical CenterWithdrawnIschemic Cardiomyopathy | Chronic Ischemic CardiomyopathyUnited States
-
Celladon CorporationCompletedHeart Failure | Cardiomyopathies | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyUnited States, United Kingdom, Belgium, Germany, Poland, Israel, Netherlands, Hungary, Denmark, Sweden
-
Rabin Medical CenterUnknownHeart Failure | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyIsrael
-
Celladon CorporationTerminatedHeart Failure | Cardiomyopathies | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathyUnited States
-
Assistance Publique - Hôpitaux de ParisCelladon CorporationTerminatedIschemic Cardiomyopathy | Non-ischemic Cardiomyopathy | Heart Failure CongestiveFrance
-
University of Cape TownMedtronicSuspendedDilated Cardiomyopathy | Ischemic Cardiomyopathy | Non-ischemic CardiomyopathySouth Africa
-
Duke UniversityCompletedCardiomyopathy (Ischemic or Non-Ischemic)United States
-
Cairo UniversityNot yet recruiting
-
Navy General Hospital, BeijingFirst People's Hospital of Foshan; General Hospital of Armed Police, Beijing; PLA General Hospital, BeijingUnknown
Clinical Trials on Intramyocardial Injection of stem cells via NOGA Mapping
-
Losordo, Douglas, M.D.TerminatedMyocardial Ischemia | Cardiovascular Disease | Congestive Heart FailureUnited States
-
Odessa National Medical UniversityUnknownHeart FailureUkraine
-
Cardiocentro TicinoTerminatedChronic Ischemic Heart DiseaseSwitzerland
-
German Heart InstituteMiltenyi Biomedicine GmbHCompletedCongestive Heart Failure | Previous Myocardial Infarction | Coronary Artery Disease With Need for Bypass Surgery | Myocardial Ischemia, Angina PectorisGermany
-
Ministry of Health, BrazilMinistry of Science and TechnologyTerminatedCoronary Artery Disease | Ischemic Heart DiseaseBrazil
-
Angioblast SystemsUnknownMyocardial InfarctionUnited States
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart Failure, CongestiveUnited States
-
Joshua M HareWithdrawnMyocardial Infarction | Chronic Ischemic Left Ventricular DysfunctionUnited States
-
MD Stem CellsUnknownGlaucoma | Macular Degeneration | Retinal Disease | Hereditary Retinal Dystrophy | Optic Nerve DiseaseUnited States
-
University of HelsinkiUnknownMyocardial Infarction | Coronary Artery Disease | Heart FailureFinland